Mandate

Vinge has advised Vicore Pharma Holding AB (publ) in connection with a directed share issue

Vinge has advised Vicore Pharma Holding AB (publ) in connection with a directed share issue, whereby Vicore Pharma receives gross proceeds of SEK 200 million.

The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process. Vicore Pharma intends to use the issue proceeds to finance preparations for Phase 2b trial in idiopathic pulmonary fibrosis (IPF) including scale-up and manufacturing whilst continuing and completing the IPF AIR trial.

Vinge’s team has consisted of Rikard Lindahl, Joel Magnusson and Annie Fällström.

 

Related

Vinge has advised Röko in connection with its listing on Nasdaq Stockholm

Vinge has advised Röko AB (publ) (“Röko”) in connection with its listing on Nasdaq Stockholm. The prospectus was published on March 4, 2025 and the first day of trading is March 11, 2025.
March 11, 2025

Vinge has advised Ingrid Capacity in new co-operation with Locus Energy, one of SEB Nordic Energy's portfolio companies

Vinge has advised Ingrid Capacity in connection with a new project together with Locus Energy, a leading Nordic energy infrastructure company owned by SEB Asset Management's SEB Nordic Energy fund, to develop Finland's largest and one of the Nordic region's largest battery storage systems.
March 07, 2025

Vinge has advised Great Security and Garda Group in connection with the acquisition of Comdate Norrlarm

Vinge has advised Great Security, one of Sweden’s largest security companies, in connection with the acquisition of Comdate Norrlarm, the largest independent alarm and security company in northern Sweden. The acquisition strengthens Great Security’s presence in the region and provides direct access to this geographical market.
March 06, 2025